Zimmer Biomet Holdings Inc Valuation – March 2018 $ZBH

Company Profile (obtained from Marketwatch): Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products, sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. The company operates through three geographical segments: America, Europe and Asia Pacific. The Americas segment comprises principally of the U.S. and includes other North, Central and South American markets. The Europe segment comprises principally of Europe and includes the Middle East and African markets. The Asia Pacific segment comprises primarily of Japan and includes other Asian and Pacific markets. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

ZBH Chart

ZBH data by YCharts


Downloadable PDF version of this valuation:

ModernGraham Valuation of ZBH – March 2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $24,470,897,660 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.50 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 73.55% Pass
6. Moderate PEmg Ratio PEmg < 20 21.75 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.10 Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.50 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 5.96 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $5.56
MG Growth Estimate 4.83%
MG Value $100.95
Opinion Overvalued
MG Grade D
MG Value based on 3% Growth $80.59
MG Value based on 0% Growth $47.24
Market Implied Growth Rate 6.62%
Current Price $120.86
% of Intrinsic Value 119.73%

Zimmer Biomet Holdings Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history, and the high PEmg ratio. The Enterprising Investor has concerns regarding the level of debt relative to the current assets. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $4.2 in 2014 to an estimated $5.56 for 2018. This level of demonstrated earnings growth does not support the market’s implied estimate of 6.62% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Zimmer Biomet Holdings Inc revealed the company was trading above its Graham Number of $98.9. The company pays a dividend of $0.96 per share, for a yield of 0.8% Its PEmg (price over earnings per share – ModernGraham) was 21.75, which was below the industry average of 43.8, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-47.61.

Zimmer Biomet Holdings Inc scores quite poorly in the ModernGraham grading system, with an overall grade of D.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$47.61
Graham Number $98.90
PEmg 21.75
Current Ratio 1.50
PB Ratio 2.10
Current Dividend $0.96
Dividend Yield 0.79%
Number of Consecutive Years of Dividend Growth 2

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2017
Total Current Assets $4,515,300,000
Total Current Liabilities $3,020,200,000
Long-Term Debt $8,917,500,000
Total Assets $25,964,500,000
Intangible Assets $19,021,800,000
Total Liabilities $14,228,700,000
Shares Outstanding (Diluted Average) 204,000,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $7.50
Dec2017 $8.90
Dec2016 $1.51
Dec2015 $0.77
Dec2014 $4.20
Dec2013 $4.54
Dec2012 $4.29
Dec2011 $4.03
Dec2010 $2.97
Dec2009 $3.32
Dec2008 $3.72
Dec2007 $3.26
Dec2006 $3.40
Dec2005 $2.93
Dec2004 $2.19
Dec2003 $1.64
Dec2002 $1.31
Dec2001 $0.77
Dec2000 $0.91

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $5.56
Dec2017 $4.39
Dec2016 $2.44
Dec2015 $3.13
Dec2014 $4.20
Dec2013 $4.08
Dec2012 $3.79
Dec2011 $3.51
Dec2010 $3.28
Dec2009 $3.40
Dec2008 $3.33
Dec2007 $2.98
Dec2006 $2.66
Dec2005 $2.11
Dec2004 $1.59
Dec2003 $1.17
Dec2002 $0.82

Recommended Reading:

Other ModernGraham posts about the company

Zimmer Biomet Holdings Inc. Analysis – September 2015 Update $ZBH

Other ModernGraham posts about related companies

Henry Schein Inc Valuation – March 2018 $HSIC
Medtronic PLC Valuation – March 2018 $MDT
UnitedHealth Group Inc Valuation – February 2018 $UNH
VCA Inc Valuation – Initial Coverage $WOOF
Universal Health Services Inc Valuation – August 2017 $UHS
Telefex Inc Valuation – Initial Coverage $TFX
BIO-TECHNE Corp Valuation – Initial Coverage $TECH
LifePoint Health Inc Valuation – Initial Coverage $LPNT
Psychemedics Corp Valuation – April 2017 $PMD
Community Health Systems Valuation – Initial Coverage $CYH


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.






Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.